PMID- 30732222
OWN - NLM
STAT- MEDLINE
DCOM- 20190226
LR  - 20231006
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 6
DP  - 2019 Feb
TI  - Association of serum high mobility group box 1 levels with disease activity and 
      renal involvement in patients with systemic vasculitis.
PG  - e14493
LID - 10.1097/MD.0000000000014493 [doi]
LID - e14493
AB  - High mobility group box 1 (HMGB1) is a kind of proinflammatory mediator that acts 
      as an alarmin when released by dying, injured or activated cells. Previous 
      studies have reported that HMGB1 are closely linked to antineutrophil cytoplasmic 
      antibody-associated vasculitis (AAV). The present study aimed to evaluate whether 
      serum HMGB1 levels were associated with systemic vasculitis (VAs).The study 
      population consisted of 51 patients with VAs, 46 patients with essential 
      hypertension (EH) and 46 healthy controls (HC). Thirty-five patients with VAs had 
      in active stage and 16 patients with VAs in an inactive stage. Furthermore, 31 
      patients with VAs had renal involvement, the other 20 patients were selected for 
      without renal involvement. Serum HMGB1 levels were measured by enzyme-linked 
      immunosorbent assay. Associations between serum HMGB1 levels with clinical and 
      laboratory parameters were analyzed.Serum HMGB1 levels in patients with VAs were 
      significantly higher than in EH and HC (all P < .05), and no difference regarding 
      serum HMGB1 levels could be found between EH and HC (P = .208). Serum HMGB1 
      levels in VAs patients with active stage were significantly higher than those in 
      HC and VAs patients with inactive stage (all P < .05). Patients with renal 
      involvement and non-renal involvement had increased HMGB1 levels compared with HC 
      (all P < .05). In addition, serum HMGB1 levels were significantly higher in 
      patients with renal involvement compared with non-renal involvement patients 
      (P = .001). Correlation analysis showed that serum HMGB1 levels were positive 
      significant correlated with the Birmingham Vasculitis Activity Score, 
      hypersensitive C reactive protein (Hs-CRP), serum creatinine (Scr) and 24-hour 
      proteinuria (all P < .05). Among the subsets of VAs, serum HMGB1 levels were 
      significantly higher in AAV, polyarteritis nodosa (PAN) and takayasu arteritis 
      (TA) than in HC (all P < .05). More interestingly, serum HMGB1 were significantly 
      higher in patients with PAN compared with AAV and TA patients (all P < .05). 
      Furthermore, there was positive correlation between serum HMGB1 levels and 
      Hs-CRP, Scr, and 24-hour proteinuria in patients with PAN (all P < .05).Serum 
      HMGB1 levels are increased in patients with VAs compared with HC and EH and can 
      reflect the disease activity and renal involvement.
FAU - Zhu, Bin
AU  - Zhu B
AD  - Xinjiang Medical University.
AD  - Center for Hypertension of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Hypertension Institute of Xinjiang, Urumqi, Xinjiang, China.
FAU - Li, Nanfang
AU  - Li N
AD  - Xinjiang Medical University.
AD  - Center for Hypertension of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Hypertension Institute of Xinjiang, Urumqi, Xinjiang, China.
FAU - Zhu, Qing
AU  - Zhu Q
AD  - Center for Hypertension of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Hypertension Institute of Xinjiang, Urumqi, Xinjiang, China.
FAU - Wu, Ting
AU  - Wu T
AD  - Center for Hypertension of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Hypertension Institute of Xinjiang, Urumqi, Xinjiang, China.
FAU - Heizati, Mulalibieke
AU  - Heizati M
AD  - Center for Hypertension of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Hypertension Institute of Xinjiang, Urumqi, Xinjiang, China.
FAU - Wang, Guoliang
AU  - Wang G
AD  - Center for Hypertension of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Hypertension Institute of Xinjiang, Urumqi, Xinjiang, China.
FAU - Yao, Xiaoguang
AU  - Yao X
AD  - Center for Hypertension of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Hypertension Institute of Xinjiang, Urumqi, Xinjiang, China.
FAU - Luo, Qin
AU  - Luo Q
AD  - Center for Hypertension of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Hypertension Institute of Xinjiang, Urumqi, Xinjiang, China.
FAU - Liu, Shasha
AU  - Liu S
AD  - Center for Hypertension of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Hypertension Institute of Xinjiang, Urumqi, Xinjiang, China.
FAU - Liu, Shanshan
AU  - Liu S
AD  - Center for Hypertension of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Hypertension Institute of Xinjiang, Urumqi, Xinjiang, China.
FAU - Hong, Jing
AU  - Hong J
AD  - Center for Hypertension of People's Hospital of Xinjiang Uygur Autonomous Region, 
      Hypertension Institute of Xinjiang, Urumqi, Xinjiang, China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers)
RN  - 0 (HMGB1 Protein)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Biomarkers
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - HMGB1 Protein/*blood
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Kidney Diseases/*epidemiology
MH  - Male
MH  - Middle Aged
MH  - ROC Curve
MH  - Sex Factors
MH  - Systemic Vasculitis/*blood/*epidemiology/physiopathology
PMC - PMC6380849
COIS- The authors declare that they have no competing interests.
EDAT- 2019/02/09 06:00
MHDA- 2019/02/27 06:00
PMCR- 2019/02/08
CRDT- 2019/02/09 06:00
PHST- 2019/02/09 06:00 [entrez]
PHST- 2019/02/09 06:00 [pubmed]
PHST- 2019/02/27 06:00 [medline]
PHST- 2019/02/08 00:00 [pmc-release]
AID - 00005792-201902080-00103 [pii]
AID - MD-D-18-06531 [pii]
AID - 10.1097/MD.0000000000014493 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Feb;98(6):e14493. doi: 10.1097/MD.0000000000014493.